β οΈ Pre-dose (trough) concentration should be 10β15 mg/L (or 15β20 mg/L for severe infections).
π Infuse slowly to avoid βRed Man Syndromeβ β usually occurs if 1 g is given in <2 hrs.
π« Infusion rate must not exceed 10 mg/min.
π Maximum daily dose: 4 g.
π About
Always check the BNF link here.
- π Glycopeptide antibiotic (related to teicoplanin).
- π¦ Effective against Gram-positive aerobes and anaerobes, including MRSA (though resistant strains reported).
- π§ Eliminated almost entirely by glomerular filtration (>90%).
- π Renal function is the key determinant of dose and frequency.
βοΈ Action
- π Inhibits cell wall synthesis in Gram-positive bacteria.
- π§ͺ Blocks incorporation of peptidoglycan precursors (NAM/NAG).
- π Poorly absorbed orally β systemic infections require IV.
Vancomycin is widely used for prophylaxis, empirical, and targeted therapy. It remains central in treating multi-resistant Staphylococcus aureus.
π Indications
- π§ Pseudomembranous colitis (oral only).
- β€οΈ Infective endocarditis due to Gram-positive cocci.
- π MRSA and other resistant staphylococcal infections.
- π©Ί Catheter-related bloodstream infections.
π Dosing (check BNF / datasheet)
Indication | Dose | Frequency | Route |
Systemic infection | 15β20 mg/kg (max 2 g per dose). Severe: Loading 25β30 mg/kg. | 8β12 hrly | IV (adjust per plasma levels) |
C. difficile (first / recurrence) | 125 mg | 6-hourly | PO for 10β14 days |
Severe C. difficile | 500 mg | 6-hourly | PO/NG Β± rectal, with IV metronidazole |
π¦ Administration
- IV administration may be via intermittent infusion or (in Critical Care/Neurosurgery) continuous infusion.
- βοΈ Loading dose based on actual body weight (if CrCl >10 ml/min, not in children <16y or dialysis patients):
- <60 kg β 1 g in 250 ml NaCl 0.9% over 2 hr
- 60β90 kg β 1.5 g in 500 ml NaCl 0.9% over 3 hr
- >90 kg β 2 g in 500 ml NaCl 0.9% over 4 hr
π§ͺ Monitoring (Intermittent dosing)
- π― Pre-dose (trough) target: 15β20 mg/L (severe infections); some centres accept 10β15 mg/L.
- π Check trough just before 4th dose, then adjust accordingly.
- π΅ Monitor renal function daily in elderly/frail patients.
- β±οΈ Do not delay doses while awaiting results unless severe renal impairment or oliguria (<0.5 ml/kg/hr).
βοΈ Maintenance dosing by creatinine clearance (CrCl)
- <10 β Avoid; consult Microbiology.
- 10β19 β 500 mg IV over 1 hr, 48 hr post-load.
- 20β29 β 500 mg IV over 1 hr, 24 hr post-load.
- 30β39 β 750 mg IV over 2 hr, 24 hr post-load.
- 40β54 β 500 mg IV over 1 hr, 12 hrly.
- 55β74 β 750 mg IV over 2 hr, 12 hrly.
- 75β89 β 1 g IV over 2 hr, 12 hrly.
- 90β110 β 1.25 g IV over 3 hr, 12 hrly.
- >110 β 1.5 g IV over 3 hr, 12 hrly.
π Dose adjustments
- <10 mg/L β β dose by 50% (round to nearest 250 mg). If >1.5 g BD, seek Micro advice.
- 10β15 mg/L β Maintain dose; check renal function daily, trough twice weekly.
- >15β20 mg/L β Hold until <15 mg/L, seek Micro advice, check daily.
π Interactions
- π Ototoxic drugs (e.g. gentamicin, furosemide).
- π Nephrotoxicity risk β with ciclosporin, aminoglycosides.
β οΈ Cautions
- π©Ί Nephrotoxic and ototoxic β monitor closely.
- β±οΈ Avoid rapid infusion β risk of anaphylactoid reaction (Red Man Syndrome).
- π΅ Elderly patients at higher risk β stop if tinnitus or hearing loss develops.
β Contraindications
- π« Hypersensitivity to vancomycin or other glycopeptides.
π₯ Side Effects
- π§ Nephrotoxicity, interstitial nephritis.
- π Ototoxicity (tinnitus, hearing loss).
- π©Έ Haematological: neutropenia, thrombocytopenia.
- π‘οΈ Hypersensitivity: StevensβJohnson syndrome, TEN, anaphylaxis.
- β‘ Infusion-related: hypotension, shock, wheeze, βRed Man Syndrome.β
π References